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Abstract 
Distant metastases in dogs with cutaneous mast cell tumors (cMCT) are rare and 
incurable. The clinico-pathological features of 44 stage IV cMCT dogs were 
prospectively investigated in relation to outcome. Dogs were uniformly staged and 
followed-up, whereas treatment was not standardized. Median survival time (ST) was 
125 days. Notably, progression-free survival and ST were independent of well-known 
prognostic factors, including anatomic site, histological grade, and mutational status. 
Conversely, tumor diameter >3 cm, more than 2 metastatic sites, bone marrow 
infiltration, and lack of tumor control at the primary site were confirmed to be negative 
prognostic factors by multivariate analysis. Currently, the treatment effectiveness for 
stage IV cMCT is not ideal. Asymptomatic dogs with tumor diameter <3 cm and a low 
tumor burden, without bon  marrow infiltration may be candidates for multimodal 
treatment. The achievement of local tumor control seems to predict a better outcome 
in dogs with stage IV cMCT. 
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Introduction 
 
In dogs, cutaneous mast cell tumor (cMCTs) is a clinically heterogeneous disease. 
Cutaneous MCTs may have a low malignant potential or be extremely aggressive, 
showing local invasiveness and a high metastatic risk.1 The most important 
independent prognostic factors are histological grading (according to Patnaik and 
Kiupel grading systems) and clinical stage, as they predict the biological behavior and 
provide reliable therapeutic indication.2 
The vast majority of the clinical concerns of oncologists are related to the treatment of 
metastases, including how to eradicate, shrink or palliate the complications of 
metastatic disease. 
A significant improvement in the locoregional control of cMCT has been seen over the 
last decades thanks to the advent of new antitumoral strategies and improved 
understanding of the biology of the disease. However, this improvement does not 
seem to have significantly influenced the final survival rate in the case of de novo 
stage IV disease, a relatively rare but clinically relevant event.2-4 
 
The clinical relevance of nodal metastasis has been intensively explored, resulting in a 
poorer clinical outcome according to several studies.5-7 Particularly, histological rather 
than cytological LN staging is of crucial importance for prognosis estimation and 
therapy stratification, as it is one of the strongest prognostic parameter in curative 
cases.2,5 In node-positive cMCT, systemic chemotherapy and/or tyrosine kinase 
inhibitors (TKIs) is generally recommended. In contrast, the benefit in stage I cMCTs is 
minimal, and the decision of whether to use medical therapy depends on additional 
risk factors. Based on the above, the regional lymph node (LN) should always be 
assessed to determine the accurate stage of disease.8 
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Conversely, the clinical value of distant metastases in cMCT has been investigated 
only in a few studies.3,4 Recently it has been documented that approximately 5% of 
dogs with cMCT are diagnosed with distant metastases at initial presentation,2 yet 
their prognostic relevance has not been intensively explored, as their disease is 
considered incurable, leading to palliative treatments and/or early euthanasia in the 
majority of cases. Indeed, current information on the prognostic value of distant 
metastases is largely dependent on retrospective series that have been collected 
during several years and at multiple institutions.3,4,9 Staging procedures as well as 
molecular analysis underwent a substantial change in recent years, leading to the 
need of reconsidering the relevance of new findings for dogs with metastatic disease. 
 
The aims of this prospective study were to clarify the features of distant metastases of 
WHO stage IV cMCTs and to identify the prognostic factors for these dogs. 
 
 
Material and methods 
 
Inclusion criteria 
Members of the Italian Society of Veterinary Oncology (SIONCOV) were asked to 
participate to this prospective, multi-institutional study. Dogs were eligible for 
recruitment if they had a previously untreated, histologically confirmed cMCT and if 
they underwent complete staging demonstrating stage IV disease. 
Background information recorded for each dog included signalment, body weight, 
primary tumor description (anatomic location, largest diameter, grade according to the 
systems of Patnaik and Kiupel, c-kit mutational status),10-12 clinical stage and 
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substage; site of metastasis; date of surgery or incisional biopsy; other adjuvant 
treatments; response of the primary tumor to treatment; response of the metastatic 
sites to treatment; date of death or last follow-up examination; cause of death; and 
occurrence of treatment-related toxicity. 
Initial staging included history and physical examination, complete blood cell count 
with differential, serum biochemistry, coagulation profile, histological examination of 
the cutaneous nodule, histological or cytological examination of regional LN, thoracic 
radiographs (3 views) and abdominal ultrasound examination or total body computed 
tomography (TBCT), fine-needle aspirates of liver and spleen regardless of their 
sonographic appearance, and cytologic examination of BM obtained from the iliac 
crest. 
The regional LN was defined as the first LN in the expected lymphatic drainage, and 
was identified either by palpation or by means of ultrasound. Cytologically, LNs or 
viscera were considered metastatic, if mast cells appeared in clusters or sheets, in 
very large numbers or atypical on morphology, as previously documented.3 
Histologically, LNs were considered metastatic in the presence of aggregates of mast 
cells in sinuses (subcapsular, paracortical or medullary) or parenchyma. Giemsa stain 
was applied in the uncertain cases. Bone marrow (BM) was considered infiltrated if 
mast cells were more than 10% of all nucleated cell, or, if atypical, more than 5 % of all 
nucleated cell, as previously described.9 
Written informed consent was obtained from all owners. 
 
Treatment and response 
The type of treatment was at the investigator’s personal discretion, and included no 
therapy, surgery, radiation therapy, chemotherapy, TKI or a combination of these. 
Depending on treatment, dogs were re-assessed as follows: on a weekly basis if 
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vinblastine was administered, on a monthly basis if lomustine, TKI or no treatment was 
administered. Physical examination, fine-needle aspiration of any new lesion, and 
bloodwork were routine elements of each assessment. An abdominal ultrasound was 
repeated every 1-2 months. All responses were defined according to the RECIST 
criteria.13 Response was confirmed at least 4 weeks (for complete remission, CR, or 
partial remission, PR) or 6 weeks (for stable disease, SD) after the first documentation. 
Local tumor control was defined as objective local tumor response in addition to 
freedom from local progression. Distant tumor control was defined as objective distant 
tumor response in addition to freedom from distant progression. 
 
Statistical analysis 
Progression free interval (PFI) was calculated from the date of stage IV diagnosis to 
the date of loco-regional and/or distant tumor progression. Survival time (ST) was 
calculated from the date of stage IV diagnosis to the date of last visit or death. Dogs 
lost to follow-up or dead due to MCT-unrelated causes were right-censored at the last 
date of known status or at the date of death, respectively. 
The following factors were investigated for prognostic significance: age, sex, weight, 
anatomic location of primary tumor, primary tumor diameter, regional LN metastasis, 
number of metastatic sites, BM infiltration, substage, histopathological grade (Patnaik 
and Kiupel), c-kit mutational status, measurable primary tumor, type of treatment 
(surgery vs radiation therapy vs medical treatment), type of medical treatment 
(chemotherapy vs TKI), treatment-related toxicity, local and distant tumor control. 
The influence of these factors on PFI and ST was investigated with a univariate Cox 
regression analysis. Median PFI and ST were assessed by means of the Kaplan-Meier 
survival curves. Factors that on univariate analysis had a P value < 0.05 were further 
tested for independence in a multivariate Cox proportional hazard model. 
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Statistical analysis was performed with SPSS Statistics v.19 (IBM, Somers, NY, USA). 
Significance was set at P < 0.05. 
 
 
Results  
 
Dogs and MCT Demographics 
Between 2011 and 2016, 44 dogs matched the inclusion criteria and were enrolled. 
There were 16 (36.4%) mixed breed dogs, 7 (15.9%) Labrador Retrievers, 4 (9.1%) 
Boxers, 3 (6.8%) French Bouledogue, 2 (4.5%) Yorkshire terrier, 2 (4.5%) Maltese, 
and one (2.3%) each of the following: Shih-Tzu, Beagle, American Staffordshire terrier, 
Dobermann, Pinscher, Argentine Mastiff, Bullmastiff, Pitbull terrier, Boston terrier, and 
Malinois. Twenty-three (52.3%) dogs were female (14 spayed), and 21 (47.7%) were 
male (5 castrated). Median age was 9 years (range, 2 to 14 years), and median weight 
was 25.2 kg (range, 2.5 to 47.5 kg). 
Mast cell tumors were in various locations, including 11 (25%) dogs with MCTs on 
head and neck, 10 (22.7%) dogs with tumors on proximal limbs (above elbow/ knee), 6 
(13.6%) dogs with MCTs on the thoracic wall, 3 (6.8%) dogs with digital tumors, 3 
(6.8%) dogs with mammary MCTs, 3 (6.8%) dogs with tumors on the scrotum, 2 
(4.5%) dogs with MCTs on the abdominal wall, 2 (4.5%) dogs with axillary MCTs, 2 
(4.5%) dogs with tumors on the prepuce, 1 dog (2.3%) with MCT on the vulva and 1 
dog (2.3%) with MCT on distal limb (distal to knee/ elbow). 
Median tumor diameter was 3.15 cm (range, 0.3 to 20 cm). 
Twenty-six (59.1%) dogs were asymptomatic (substage a), whereas 18 (40.9%) dogs 
showed clinical signs and symptoms at diagnosis of stage IV disease (substage b), 
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including vomiting, diarrhea, localized and/or generalized pruritus, and regional 
edema. 
 
All dogs underwent complete staging work-up, as previously described; 35 (79.5%) 
dogs underwent three-view thoracic radiographs and abdominal ultrasound, whereas 9 
(20.5%) dogs had a TBCT performed.  
All dogs had distant metastatic disease: 22 (50%) dogs had splenic and hepatic 
metastasis, 6 (13.6%) dogs had hepatic metastasis, 3 (6.8%) dogs had splenic 
metastasis, 3 (6.8%) dogs had metastases in the spleen, liver and non-regional LNs, 3 
(6.8%) dogs had metastases in the spleen, liver and BM, 2 (4.5%) dogs had 
metastases in the spleen and BM, 1 (2.3%) had metastases in the spleen, liver, BM 
and peripheral blood, 1 (2.3%) had splenic, hepatic and pulmonary metastases, 1 
(2.3%) had metastases in the spleen and non-regional LNs, 1 (2.3%) had splenic, 
renal and BM metastases, and 1 (2.3%) had metastases in the spleen, liver, BM, and 
non-regional LNs.  
Forty (90.9%) dogs had also metastasis in the regional LN, while 4 (9.1%) dogs did 
not. Lymph node metastases were confirmed in 30 (68.2%) dogs by means of 
histopathology, whereas the remaining 10 (22.7%) dogs had only a cytologic 
diagnosis. Regarding the 4 dogs without LN metastasis, the diagnosis was by means 
of histopathology in 3 (75%) of them, and by means of cytology in 1 (25%) dog. 
Visceral metastases were confirmed in all cases by means of cytology. 
 
Histopathology was available for all primary cMCTs: 22 (50%) dogs had Patnaik’s 
grade 2 cMCTs, 20 (45.5%) dogs had grade 3 MCTs, and 2 (4.5%) dogs had grade 1 
cMCTs. Regarding the Kiupel’s grading system, 28 (63.6%) tumors were classified as 
high grade cMCTs, and 16 (36.4%) as low grade cMCTs. 
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Tissue specimens of all dogs were suitable for c-kit genotyping.  
Internal tandem duplications were detected in 13 (29.5%) cMCTs: 8 in exon 11, 4 in 
exons 11 and 12, and 1 in exon 8. Nine (20.5%) silent single nucleotide 
polymorphisms (SNPs) were detected in exon 8, and 1 (2.3%) silent SNP in exon 11. 
Twenty-one (47.7%) dogs had wild type (WT) genotype (exons 8, 9, 11, and 12).  
 
Treatment and clinical follow-up 
Surgery was the primary treatment for 31 (70.5%) dogs; in 18 of them the MCT 
recurred shortly (within 30 days) postoperatively and those dogs had consequently 
macroscopic disease when first referred. Twenty-eight of the 31 dogs also received 
systemic treatment postoperatively, while 2 of 31 dogs also received curative-intent 
radiation therapy. Curative-intent radiation therapy ranged from 14 to 16 fractions for a 
total dose of 45 to 48 Gy. 
Ten (22.7%) of 44 dogs only received medical treatment as primary therapy. 
Three (6.8%) of 44 dogs received a combination of palliative radiation therapy and 
systemic treatment as primary therapy. Palliative radiation therapy consisted of 5 
fractions of 6 to 8 Gy each. 
Overall, 41 (93.2%) dogs received systemic therapy, consisting of TKIs (n=21), dose-
intense chemotherapy (n=7), or a combination of these (n=13). 
Twelve (31.6%) out of the 38 dogs receiving medical treatment experienced treatment-
related toxicity, consisting of grade 1 lethargy (n=1), grade 1 (n=2), 2 (n=2) and 3 
(n=1) gastro-intestinal side effects, grade 1 (n=1), 2 (n=1) and 3 (n=2) hematologic 
toxicity, and grade 2 hepatotoxicity (n=2).  
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When evaluating the primary MCT, 31 (70.5%) dogs had measurable disease and 
were therefore assessable for antitumor response. Three (9.7%) dogs achieved CR, 
12 (38.7%) dogs experienced PR, in 4 (12.9%) dogs the primary disease was stable, 
whereas in 12 (38.7%) dogs was progressive, for an overall response rate in the 
macroscopic setting of 48.4%.  
When considering metastatic disease in this group of dogs (including nodal and 
visceral), 3 (9.7%) dogs achieved CR at their metastatic sites, 2 (6.5%) dogs achieved 
PR, 6 (19.4%) dogs obtained SD, and 20 (64.5%) dogs progressed. Complete 
response was documented by imaging and confirmative cytology. 
 
None of the 13 (29.5%) dogs with surgically removed cMCT progressed at the primary 
site during the study period. 
When considering metastatic disease in this group of dogs (including nodal and 
visceral), 4 (30.8%) dogs obtained CR, 4 (30.8%) dogs obtained PR, 4 (30.8%) dogs 
were stable, and 1 (7.7%) dog progressed. Overall, median PFI was 45 days (95% CI, 
9.4-80.6 days). 
 
The median follow-up time was 306 days (range, 16 to 1246 days). Thirty-nine (88.6%) 
dogs died or were euthanized within the follow-up period; among them, 38 died 
because of MCT-related disease and 1 because of a brain tumor after 380 days. Five 
(11.4%) dogs were alive at the end of the study. Overall, median ST was 125 days 
(95% CI, 84.8 to 165.2 days). 
 
Analysis of prognostic factors 
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In univariate analysis, factors significantly associated with PFI were: tumor diameter 
>3 cm, more than 2 metastatic sites, substage b, and measurable primary tumor 
(Table 1).  
Factors significantly associated with ST were: tumor diameter >3 cm, regional LN 
metastases, more than 2 metastatic sites, BM infiltration, substage b, and lack of local 
and distant tumor control (Table 2). 
In multivariate analysis, tumor diameter >3 cm, more than 2 metastatic sites and 
measurable primary tumor at diagnosis of stage IV disease were still significantly 
associated with PFI, whereas the factors associated with ST were BM infiltration and 
lack of local tumor control (Tables 3 and 4). 
Age, sex, weight, anatomic location of the primary tumor, histopathological grade, 
mutational status, type of treatment, and onset of treatment-related toxicity were not 
significantly associated with either PFI or ST.  
 
 
Discussion 
 
Approximately 5% of dogs with cMCT have distant metastasis at initial diagnosis, with 
liver, spleen, BM and distant LNs being the major sites of metastatic involvement.2  
Distant metastases are for most solid tumors decisive life-threatening events. Up to 
date, based on the recent literature, stage IV cMCT is perceived to be a very 
aggressive and ominous disease carrying a poor prognosis, with reported survival 
times ranging from 34 to 100 days among a total of 31 dogs examined in 3 studies.3,4,9 
Due to its incurability, many veterinary oncologists do not advice to pursue any 
oncologic treatment, and rather euthanasia is suggested or even carried out right after 
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staging results. Moreover, potential chemotherapy-related toxicity leads owners to opt 
out of medical oncologic treatment for their dogs.9 
Unfortunately, the studies published so far have only marginally improved the 
understanding of the outcome of dogs with stage IV disease, as no systematic body of 
knowledge on the clinical features, diagnosis, or treatment of such cases is available. 
Importantly, there are no guidelines on how to manage dogs presenting with stage IV 
cMCT, and decisions are often left to provider and owner preferences. 
To our knowledge, this is the largest case series of dogs with de novo stage IV cMCT 
enrolled prospectively, uniformly staged and followed-up. 
 
In this study, dog characteristics were similar to previous publications with median age 
of diagnosis of 9 years and no sex predilection.8 In agreement with the literature, 
Labrador retrievers were over-represented.14 While Boxers have been described to 
carry a better prognosis,1,8,10 in the current study this breed was slightly over-
represented, suggesting that the biologic behavior cannot be entirely anticipated by 
the signalment. 
The same holds true for anatomic site of primary tumor development. While 23 of 44 
dogs (52.3%) had MCTs that developed in sites described to behave in a more 
malignant fashion,8 21 (47.7%) did not. 
Of utmost importance is the variability of grading that was documented in this series of 
dogs. Twenty-two (50%) dogs had Patnaik grade 1 and 2 cMCTs, and 16 (36.4%) had 
Kiupel low-grade cMCTs, thereby limiting the utility of histologic evaluation as the sole 
predictor of outcome.2 In addition, the statistical evaluation confirmed the non-
prognostic role of histological grade in the presence of verified metastatic disease, 
leading to hypothesize that the histopathological evaluation might not be so essential 
for stage IV disease. 
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It has been reported that cMCTs harboring c-kit mutations, particularly some ITDs, 
have a poorer prognosis compared to those with WT c-kit genes.15-17 Mutational status 
was documented in all dogs, and surprisingly 21 (47.7%) dogs had WT genotyping 
(exons 8, 9, 11, and 12).  
As a whole, these data suggest that multiple variables need to be taken into 
consideration when predicting the biological behavior of cMCTs, with complete staging 
work-up being fundamental.  
 
Our clinical data confirm the poor outcome of stage IV disease, with a median ST of 
125 days. Nevertheless, based on our results, the diagnosis of distant metastatic 
disease is not always necessarily a death sentence, as selected dogs may enjoy 
prolonged survival, clearly suggesting that additional factors in concert need to be 
taken into account to define prognosis.  
Indeed, the current study identified some prognostic indicators in dogs with stage IV 
cMCT. Surprisingly, while the PFI and ST for this group of dogs were largely 
independent of well-known prognostic factors, such as anatomic site, histological 
grade, and mutational status,10,11,15,19,20 some reported negative prognostic factors 
were confirmed. 
 
That presence of systemic symptoms is associated with outcome has been already 
verified.8,21 In our study, substage was an indicator of PFI and ST by univariate 
analysis; however, this relationship was not confirmed by multivariate analysis. 
In agreement with previous studies, dogs with cMCTs larger than 3 cm had a 
significantly shorter PFI and ST.2,21,22 The relationship with PFI was confirmed as 
independent factor by multivariate analysis. Accordingly, the presence of measurable 
primary MCT at diagnosis of stage IV disease was associated with significantly 
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shorter PFI by multivariate analysis. In 18 of these 31 dogs, the measurable tumor 
represented recurrent disease shortly after a first surgery. As a whole, these results 
show that bulky disease may not be amenable to efficient local treatment, thereby 
worsening prognosis. 
 
Metastatic burden also had a negative influence on PFI and ST according to 
univariate analysis, with more than 2 metastatic sites being associated with a poor 
outcome, but was not confirmed as independent factor for ST by multivariate 
analysis. 
The concept of the regional LN has been already validated in dogs with cMCT.5,23 In 
general, tumor cells at a specific anatomical site will first drain preferentially to the 
corresponding LN before reaching other LNs in the same regional basin and then 
spreading to distant sites, thereby following an orderly progression from local tumor 
growth at the primary site to the regional LN, followed by distant metastatic 
dissemination.24 As a result, close examination of the regional LN is critical, as this 
provides valuable clinical information regarding the status of disease progression.5-7 
Occasionally, cancer cells can spread to the systemic sites alone via the vascular 
system, thereby skipping the regional LN.25 
In the current series, 4 of 44 (9.1%) dogs had no regional LN involvement despite the 
presence of distant metastases. Three of them underwent lymphadenectomy and 
histopathological evaluation, whereas one dog had cytological evaluation only. 
However, this dog was serially evaluated by means of LN cytology sampling during 
follow-up visits to confirm the absence of nodal metastasis (data not shown). Nodal 
metastasis was associated with ST, with dogs without LN metastasis living 
significantly longer than those with nodal disease (940 versus 109 days, 
respectively). The biologic role of nodal metastases and their paradigm of orderly 
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progression in cancer spread remains to be defined, but according to our results it 
may be possible that a small percentage of cMCT has different mechanisms of 
disease spread. 
 
As already documented,9 BM infiltration has important biologic implications, and was 
significantly associated with shorter ST by multivariate analysis. Disseminated tumor 
cells found in the BM may serve as reservoir of dormant cancer cells, representing 
the founder cells of overt metastases.26 In general, disseminated cancer cells are 
considered to have a more aggressive phenotype, as they have developed the ability 
to home and survive in the BM, and evade the host immune recognition at the 
regional LN, being then able to colonize distant sites.26 Of note, only 1 of the 8 dogs 
(12.5%) with BM infiltration had concurrent circulating neoplastic cells. This is in 
agreement with the human literature, showing that circulating neoplastic cells are 
numerically fewer than disseminated neoplastic cells, thereby requiring extremely 
sensitive analytical methods for their detection.27,28 As a consequence, BM should 
always be part of the staging work-up in dogs with nodal and/or visceral metastasis, 
as it indicates a higher tumor burden and a worse prognosis (median ST 35 days vs 
146 days, with and without BM infiltration, respectively).  
 
Lack of tumor control at the primary and distant sites was significantly associated 
with ST; however only tumor control at the primary site retained significance by 
multivariate analysis. The variability in outcome is in part dependent on the type of 
treatment. The dogs receiving local treatment (surgery and/or radiation therapy) plus 
systemic treatment (chemotherapy or TKI or both) had a better outcome than those 
that did not. Similar results have been observed in a previous study,14 suggesting 
that surgical resection of the primary cMCT followed by systemic therapy offers a 
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significant survival advantage compared to dogs receiving chemotherapy without 
local control. 
 
This study has some limitations. Although LN metastases were confirmed or ruled 
out by means of histopathology in the majority (75%) of cases, visceral metastases 
were confirmed by cytology in all cases. Nevertheless, the presence of several 
aggregates of mast cells, and their atypical morphology rendered the hypothesis of 
non-neoplastic mast cells unlikely in these cases. 
Within our series, there was heterogeneity of treatment, as many owners elected not 
to pursue aggressive approaches to management due to the poor prognosis. 
 
In conclusion, stage IV cMCTs are rare and associated with a poor outcome. 
Nevertheless, asymptomatic dogs with tumor diameter <3 cm and a low tumor 
burden, without BM infiltration may be candidates for local treatment plus systemic 
treatment. Stage IV dogs without LN metastasis may enjoy a surprisingly prolonged 
survival. The achievement of local tumor control seems to be the main predictor of 
better outcome in dogs with stage IV cMCT.  
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Table 1 – Univariate Cox regression analysis of variables potentially associated with 
increased risk of disease progression in 44 dogs with stage IV cutaneous mast cell tumors. 
Variable No. of dogs Median PFI 
(days) 
HR 95% CI P 
Age   1.25 0.66-2.38 0.489 
> 9 years‡  24 81    
≤ 9 years 20 36    
Sex   1.12 0.59-2.14 0.721 
female  21 36    
male 23 81    
Neutered   1.01 0.53-1.94 0.974 
no 25 45    
yes 19 81    
Weight   1.38 0.72-2.65 0.330 
≤ 25.2 kg‡ 22 41    
> 25.2 kg 22 46    
Negative prognostic 
site of primary tumor 
  1.02 0.54-1.94 0.949 
no 23 46    
yes 21 45    
Tumor diameter at 
presentation 
> 3 cm 
≤ 3 cm 
 
23 
21 
 
35 
120 
2.67 1.31-5.42 0.007* 
Node metastasis   34.04 0.91-1277.57 0.056 
yes  40 42    
no 4 940    
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More than 2 metastatic 
sites 
  2.84 1.22-6.61 0.016* 
yes  32 35    
no 12 84    
Bone marrow 
infiltration 
  1.52 0.62-3.75 0.359 
yes  8 29    
no 36 45    
Substage   2.16 1.05-4.43 0.036* 
b  18 41    
a 26 70    
Patnaik grade   1.48 0.76-2.89 0.251 
3 20 46    
1, 2 24 41    
Kiupel grade   1.23 0.62-2.42 0.553 
high grade 28 46    
low grade 16 36    
c-Kit mutations   1.02 0.52-1.97 0.961 
yes 15 45    
no 29 46    
Measurable primary 
tumor at diagnosis of 
stage IV disease 
yes  
no 
 
 
 
31 
13 
 
 
 
29 
125 
2.77 1.28-5.95 0.009* 
Surgery   1.02 0.51-2.03 0.951 
no 13 41    
yes 31 46    
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Radiation therapy   1.14 0.44-2.96 0.782 
no 39 45    
yes 5 120    
Medical treatment   1.47 0.45-4.82 0.528 
no 3 21    
yes 41 46    
Type of medical 
treatment 
  1.13 0.53-2.41 0.709 
TKI only  7 41    
chemotherapy only 21 42    
chemotherapy and 
TKI 
13 90    
Use of TKIs in the 
presence of c-Kit 
mutations 
  1.17 0.59-2.33 0.655 
yes  13 45    
no 31 46    
Treatment toxicity   1.01 0.50-2.03 0.972 
yes  13 87    
no 31 42    
PFI = progression free interval; HR = hazard ratio; CI = confidence interval; TKI = tyrosine 
kinase inhibitor; ‡ = median value; * = significant. 
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Table 2 – Univariate Cox regression analysis of variables potentially associated with 
increased risk of tumor-related death in 44 dogs with stage IV cutaneous mast cell tumors. 
Variable No. of dogs Median OS 
(days) 
HR 95% CI P 
Age   1.00 0.52-1.92 0.994 
> 9 years‡  20 109    
≤ 9 years 24 146    
Sex   1.08 0.57-2.05 0.816 
female  23 110    
male 21 146    
Neutered   1.06 0.55-2.03 0.872 
no 25 101    
yes 19 146    
Weight   1.60 0.83-3.09 0.163 
≤ 25.2 kg‡ 22 109    
> 25.2 kg 22 133    
Negative prognostic 
site of primary tumor 
  1.24 0.65-2.34 0.512 
yes  13 109    
no 31 146    
Tumor diameter at 
presentation 
> 3 cm 
≤ 3 cm 
 
 
23 
21 
 
 
77 
209 
2.25 1.16-4.36 0.016* 
Node metastasis   40.15 1.09-1477.26 0.045* 
yes  40 109    
no 4 940    
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More than 2 metastatic 
sites 
  3,21 1.38-7.48 0.007* 
yes  32 77    
no 12 198    
Bone marrow 
infiltration 
  3.56 1.45-8.76 0.006* 
yes  8 35    
no 36 146    
Substage   2.95 1.45-6.00 0.003* 
b 18 72    
a 26 180    
Patnaik grade   1.50 0.78-2.91 0.226 
3 20 77    
1, 2 24 150    
Kiupel grade   1.34 0.68-2.64 0.399 
high grade  28 101    
low grade 16 154    
c-Kit mutations   1.19 0.61-2.31 0.604 
yes  15 77    
no 29 133    
Measurable primary 
tumor at diagnosis of 
stage IV disease 
yes  
no 
 
 
 
31 
13 
 
 
 
110 
180 
1.79 0.86-3.75 0.120 
Surgery   1.06 0.52-2.15 0.870 
yes  31 109    
no 13 146    
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Radiation therapy   1.22 0.47-3.15 0.688 
no 39 109    
yes 5 209    
Medical treatment   1.48 0.35-6.19 0.591 
yes  41 110    
no 3 180    
Type of medical 
treatment 
  1.11 0.52-2.35 0.688 
TKI only  7 154    
chemotherapy only 21 109    
chemotherapy and 
TKI 
13 146    
Use of TKIs in the 
presence of c-Kit 
mutations 
  1.39 0.70-2.79 0.347 
yes  13 77    
no 31 133    
Treatment toxicity   1.12 0.55-2.29 0.750 
yes  13 133    
no 31 125    
Local tumor control   5.37 2.40-12.01 <0.001* 
no  12 28    
yes 32 180    
Distant tumor control   2.68 1.38-5.23 0.004* 
no  21 32    
yes 23 180    
OS = overall survival; HR = hazard ratio; CI = confidence interval; TKI = tyrosine kinase 
inhibitor; ‡ = median value; * = significant. 
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Table 3. Multivariate Cox regression analysis of variables potentially associated with 
increased risk of disease progression in 44 dogs with stage IV cutaneous mast cell tumors. 
Variable HR 95% CI P 
Tumor diameter > 3 cm at presentation 3.30 1.39-7.82 0.007* 
More than 2 metastatic sites 2.91 1.18-7.18 0.021* 
Substage b 1.08 0.40-2.50 0.801 
Measurable primary tumor at diagnosis of stage IV 
disease 
2.41 1.08-5.40 0.034* 
* = significant. 
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Table 4. Multivariate Cox regression analysis of variables potentially associated with 
increased risk of tumor-related death in 44 dogs with stage IV cutaneous mast cell tumors. 
Variable HR 95% CI P 
Tumor diameter > 3 cm at presentation 1.77 0.77-4.09 0.182 
Node metastasis  786953.16 0.00-
4.58E238 
0.960 
More than 2 metastatic sites 1.31 0.53-3.24 0.563 
Bone marrow infiltration 3.30 1.16-9.42 0.026* 
Substage b 1.32 0.57-3.02 0.518 
Lack of local tumor control 4.28 1.41-13.01 0.010* 
Lack of distant tumor control 1.14 0.47-2.78 0.776 
* = significant. 
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